Skip to Content
COVID-19 Resources
Translational Research Program (TRP)
Contact CIP
Show menu
Search this site
Last Updated: 02/21/20

Bladder SPOREs

Bladder cancer has an estimated 80,470* new cases and 17,670 deaths in 2019 and has a higher incidence in men than in women. The percent of patients surviving for 5 years is 77.1%. The Memorial Sloan Kettering Cancer Center Bladder SPORE was funded in 2018 with goals to 1- Develop predictive biomarkers based on patients’ response or resistance to chemotherapy and immunotherapy, 2- Access a large set of familial patient samples (>1000) and analyze by genome sequencing technologies to identify novel inherited susceptibility genes, 3- Understand why patients treated with immunotherapy (Anti PD-L1) have limited response and find predictive markers of response and resistance to guide combination therapies, and 4- Explore immunologic predictors of BCG immunotherapy.